Sublingual Atropine for sialorrhea secondary to parkinsonism: A pilot study
Identifieur interne : 006284 ( Main/Merge ); précédent : 006283; suivant : 006285Sublingual Atropine for sialorrhea secondary to parkinsonism: A pilot study
Auteurs : H. Christopher Hyson [Canada] ; Andrew M. Johnson [Canada] ; Mandar S. Jog [Canada]Source :
- Movement Disorders [ 0885-3185 ] ; 2002-11.
English descriptors
- KwdEn :
- Administration, Sublingual, Aged, Aged, 80 and over, Atropine (administration & dosage), Atropine (adverse effects), Delusions (chemically induced), Female, Hallucinations (chemically induced), Humans, Male, Middle Aged, Parkinson's disease, Parkinsonian Disorders (drug therapy), Pilot Projects, Salivation (drug effects), Sialorrhea (drug therapy), Treatment Outcome, atropine, sialorrhea.
- MESH :
- chemical , administration & dosage : Atropine.
- chemical , adverse effects : Atropine.
- chemically induced : Delusions, Hallucinations.
- drug effects : Salivation.
- drug therapy : Parkinsonian Disorders, Sialorrhea.
- Administration, Sublingual, Aged, Aged, 80 and over, Female, Humans, Male, Middle Aged, Pilot Projects, Treatment Outcome.
Abstract
Sialorrhea is a relatively common symptom in idiopathic Parkinson's disease and related conditions for which most of the accepted treatments are either highly invasive or may cause substantial systemic side effects. This study describes an open‐label pilot study of sublingual atropine drops for the treatment of sialorrhea in 7 patients (6 with Parkinson's disease, 1 with progressive supranuclear palsy). Participants demonstrated statistically significant declines in saliva production, both objectively and subjectively. Self‐reported drooling severity showed a significant decline between baseline and 180 minutes, t(6) = 3.240 P < 0.025 (η2 = 0.636), and between baseline and 1 week, t(6) = 4.583 P < 0.005 (η2 = 0.778). Objectively measured saliva production decreased significantly between baseline and the 1‐week follow‐up, t(6) = 2.711 P < 0.05 (η2 = 0.551). Delirium occurred in 1 patient (concurrent with a urinary tract infection), and 2 patients experienced worsening of hallucinations (active hallucinosis was concealed by both individuals to allow participation in the trial). The remaining trial participants did not experience any anticholinergic side effects. This trial shows that, in selected patient populations, sublingual atropine is a simple and inexpensive treatment for sialorrhea associated with parkinsonism. © 2002 Movement Disorder Society
Url:
DOI: 10.1002/mds.10276
Links toward previous steps (curation, corpus...)
- to stream Istex, to step Corpus: 002D52
- to stream Istex, to step Curation: 002D52
- to stream Istex, to step Checkpoint: 002B70
- to stream PubMed, to step Corpus: 003904
- to stream PubMed, to step Curation: 003904
- to stream PubMed, to step Checkpoint: 003925
- to stream Ncbi, to step Merge: 000947
- to stream Ncbi, to step Curation: 000947
- to stream Ncbi, to step Checkpoint: 000947
Links to Exploration step
ISTEX:07A65F99973DA9BFA8C22CFE208BE2B92BA3D355Le document en format XML
<record><TEI wicri:istexFullTextTei="biblStruct"><teiHeader><fileDesc><titleStmt><title xml:lang="en">Sublingual Atropine for sialorrhea secondary to parkinsonism: A pilot study</title>
<author><name sortKey="Hyson, H Christopher" sort="Hyson, H Christopher" uniqKey="Hyson H" first="H. Christopher" last="Hyson">H. Christopher Hyson</name>
</author>
<author><name sortKey="Johnson, Andrew M" sort="Johnson, Andrew M" uniqKey="Johnson A" first="Andrew M." last="Johnson">Andrew M. Johnson</name>
</author>
<author><name sortKey="Jog, Mandar S" sort="Jog, Mandar S" uniqKey="Jog M" first="Mandar S." last="Jog">Mandar S. Jog</name>
</author>
</titleStmt>
<publicationStmt><idno type="wicri:source">ISTEX</idno>
<idno type="RBID">ISTEX:07A65F99973DA9BFA8C22CFE208BE2B92BA3D355</idno>
<date when="2002" year="2002">2002</date>
<idno type="doi">10.1002/mds.10276</idno>
<idno type="url">https://api.istex.fr/document/07A65F99973DA9BFA8C22CFE208BE2B92BA3D355/fulltext/pdf</idno>
<idno type="wicri:Area/Istex/Corpus">002D52</idno>
<idno type="wicri:Area/Istex/Curation">002D52</idno>
<idno type="wicri:Area/Istex/Checkpoint">002B70</idno>
<idno type="wicri:doubleKey">0885-3185:2002:Hyson H:sublingual:atropine:for</idno>
<idno type="wicri:source">PubMed</idno>
<idno type="RBID">pubmed:12465075</idno>
<idno type="wicri:Area/PubMed/Corpus">003904</idno>
<idno type="wicri:Area/PubMed/Curation">003904</idno>
<idno type="wicri:Area/PubMed/Checkpoint">003925</idno>
<idno type="wicri:Area/Ncbi/Merge">000947</idno>
<idno type="wicri:Area/Ncbi/Curation">000947</idno>
<idno type="wicri:Area/Ncbi/Checkpoint">000947</idno>
<idno type="wicri:doubleKey">0885-3185:2002:Hyson H:sublingual:atropine:for</idno>
<idno type="wicri:Area/Main/Merge">006284</idno>
</publicationStmt>
<sourceDesc><biblStruct><analytic><title level="a" type="main" xml:lang="en">Sublingual Atropine for sialorrhea secondary to parkinsonism: A pilot study</title>
<author><name sortKey="Hyson, H Christopher" sort="Hyson, H Christopher" uniqKey="Hyson H" first="H. Christopher" last="Hyson">H. Christopher Hyson</name>
<affiliation wicri:level="1"><country xml:lang="fr">Canada</country>
<wicri:regionArea>Movement Disorders Program, London Health Sciences Centre, London, Ontario</wicri:regionArea>
<wicri:noRegion>Ontario</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Johnson, Andrew M" sort="Johnson, Andrew M" uniqKey="Johnson A" first="Andrew M." last="Johnson">Andrew M. Johnson</name>
<affiliation wicri:level="1"><country xml:lang="fr">Canada</country>
<wicri:regionArea>University of Western Ontario, London, Ontario</wicri:regionArea>
<wicri:noRegion>Ontario</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Jog, Mandar S" sort="Jog, Mandar S" uniqKey="Jog M" first="Mandar S." last="Jog">Mandar S. Jog</name>
<affiliation wicri:level="1"><country xml:lang="fr">Canada</country>
<wicri:regionArea>Movement Disorders Program, London Health Sciences Centre, London, Ontario</wicri:regionArea>
<wicri:noRegion>Ontario</wicri:noRegion>
</affiliation>
</author>
</analytic>
<monogr></monogr>
<series><title level="j">Movement Disorders</title>
<title level="j" type="sub">Official Journal of the Movement Disorder Society</title>
<title level="j" type="abbrev">Mov. Disord.</title>
<idno type="ISSN">0885-3185</idno>
<idno type="eISSN">1531-8257</idno>
<imprint><publisher>Wiley Subscription Services, Inc., A Wiley Company</publisher>
<pubPlace>New York</pubPlace>
<date type="published" when="2002-11">2002-11</date>
<biblScope unit="vol">17</biblScope>
<biblScope unit="issue">6</biblScope>
<biblScope unit="page" from="1318">1318</biblScope>
<biblScope unit="page" to="1320">1320</biblScope>
</imprint>
<idno type="ISSN">0885-3185</idno>
</series>
<idno type="istex">07A65F99973DA9BFA8C22CFE208BE2B92BA3D355</idno>
<idno type="DOI">10.1002/mds.10276</idno>
<idno type="ArticleID">MDS10276</idno>
</biblStruct>
</sourceDesc>
<seriesStmt><idno type="ISSN">0885-3185</idno>
</seriesStmt>
</fileDesc>
<profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Administration, Sublingual</term>
<term>Aged</term>
<term>Aged, 80 and over</term>
<term>Atropine (administration & dosage)</term>
<term>Atropine (adverse effects)</term>
<term>Delusions (chemically induced)</term>
<term>Female</term>
<term>Hallucinations (chemically induced)</term>
<term>Humans</term>
<term>Male</term>
<term>Middle Aged</term>
<term>Parkinson's disease</term>
<term>Parkinsonian Disorders (drug therapy)</term>
<term>Pilot Projects</term>
<term>Salivation (drug effects)</term>
<term>Sialorrhea (drug therapy)</term>
<term>Treatment Outcome</term>
<term>atropine</term>
<term>sialorrhea</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="administration & dosage" xml:lang="en"><term>Atropine</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="adverse effects" xml:lang="en"><term>Atropine</term>
</keywords>
<keywords scheme="MESH" qualifier="chemically induced" xml:lang="en"><term>Delusions</term>
<term>Hallucinations</term>
</keywords>
<keywords scheme="MESH" qualifier="drug effects" xml:lang="en"><term>Salivation</term>
</keywords>
<keywords scheme="MESH" qualifier="drug therapy" xml:lang="en"><term>Parkinsonian Disorders</term>
<term>Sialorrhea</term>
</keywords>
<keywords scheme="MESH" xml:lang="en"><term>Administration, Sublingual</term>
<term>Aged</term>
<term>Aged, 80 and over</term>
<term>Female</term>
<term>Humans</term>
<term>Male</term>
<term>Middle Aged</term>
<term>Pilot Projects</term>
<term>Treatment Outcome</term>
</keywords>
</textClass>
<langUsage><language ident="en">en</language>
</langUsage>
</profileDesc>
</teiHeader>
<front><div type="abstract" xml:lang="en">Sialorrhea is a relatively common symptom in idiopathic Parkinson's disease and related conditions for which most of the accepted treatments are either highly invasive or may cause substantial systemic side effects. This study describes an open‐label pilot study of sublingual atropine drops for the treatment of sialorrhea in 7 patients (6 with Parkinson's disease, 1 with progressive supranuclear palsy). Participants demonstrated statistically significant declines in saliva production, both objectively and subjectively. Self‐reported drooling severity showed a significant decline between baseline and 180 minutes, t(6) = 3.240 P < 0.025 (η2 = 0.636), and between baseline and 1 week, t(6) = 4.583 P < 0.005 (η2 = 0.778). Objectively measured saliva production decreased significantly between baseline and the 1‐week follow‐up, t(6) = 2.711 P < 0.05 (η2 = 0.551). Delirium occurred in 1 patient (concurrent with a urinary tract infection), and 2 patients experienced worsening of hallucinations (active hallucinosis was concealed by both individuals to allow participation in the trial). The remaining trial participants did not experience any anticholinergic side effects. This trial shows that, in selected patient populations, sublingual atropine is a simple and inexpensive treatment for sialorrhea associated with parkinsonism. © 2002 Movement Disorder Society</div>
</front>
</TEI>
<double doi="10.1002/mds.10276"><ISTEX><TEI wicri:istexFullTextTei="biblStruct"><teiHeader><fileDesc><titleStmt><title xml:lang="en">Sublingual Atropine for sialorrhea secondary to parkinsonism: A pilot study</title>
<author><name sortKey="Hyson, H Christopher" sort="Hyson, H Christopher" uniqKey="Hyson H" first="H. Christopher" last="Hyson">H. Christopher Hyson</name>
</author>
<author><name sortKey="Johnson, Andrew M" sort="Johnson, Andrew M" uniqKey="Johnson A" first="Andrew M." last="Johnson">Andrew M. Johnson</name>
</author>
<author><name sortKey="Jog, Mandar S" sort="Jog, Mandar S" uniqKey="Jog M" first="Mandar S." last="Jog">Mandar S. Jog</name>
</author>
</titleStmt>
<publicationStmt><idno type="wicri:source">ISTEX</idno>
<idno type="RBID">ISTEX:07A65F99973DA9BFA8C22CFE208BE2B92BA3D355</idno>
<date when="2002" year="2002">2002</date>
<idno type="doi">10.1002/mds.10276</idno>
<idno type="url">https://api.istex.fr/document/07A65F99973DA9BFA8C22CFE208BE2B92BA3D355/fulltext/pdf</idno>
<idno type="wicri:Area/Istex/Corpus">002D52</idno>
<idno type="wicri:Area/Istex/Curation">002D52</idno>
<idno type="wicri:Area/Istex/Checkpoint">002B70</idno>
<idno type="wicri:doubleKey">0885-3185:2002:Hyson H:sublingual:atropine:for</idno>
</publicationStmt>
<sourceDesc><biblStruct><analytic><title level="a" type="main" xml:lang="en">Sublingual Atropine for sialorrhea secondary to parkinsonism: A pilot study</title>
<author><name sortKey="Hyson, H Christopher" sort="Hyson, H Christopher" uniqKey="Hyson H" first="H. Christopher" last="Hyson">H. Christopher Hyson</name>
<affiliation wicri:level="1"><country xml:lang="fr">Canada</country>
<wicri:regionArea>Movement Disorders Program, London Health Sciences Centre, London, Ontario</wicri:regionArea>
<wicri:noRegion>Ontario</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Johnson, Andrew M" sort="Johnson, Andrew M" uniqKey="Johnson A" first="Andrew M." last="Johnson">Andrew M. Johnson</name>
<affiliation wicri:level="1"><country xml:lang="fr">Canada</country>
<wicri:regionArea>University of Western Ontario, London, Ontario</wicri:regionArea>
<wicri:noRegion>Ontario</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Jog, Mandar S" sort="Jog, Mandar S" uniqKey="Jog M" first="Mandar S." last="Jog">Mandar S. Jog</name>
<affiliation wicri:level="1"><country xml:lang="fr">Canada</country>
<wicri:regionArea>Movement Disorders Program, London Health Sciences Centre, London, Ontario</wicri:regionArea>
<wicri:noRegion>Ontario</wicri:noRegion>
</affiliation>
</author>
</analytic>
<monogr></monogr>
<series><title level="j">Movement Disorders</title>
<title level="j" type="sub">Official Journal of the Movement Disorder Society</title>
<title level="j" type="abbrev">Mov. Disord.</title>
<idno type="ISSN">0885-3185</idno>
<idno type="eISSN">1531-8257</idno>
<imprint><publisher>Wiley Subscription Services, Inc., A Wiley Company</publisher>
<pubPlace>New York</pubPlace>
<date type="published" when="2002-11">2002-11</date>
<biblScope unit="vol">17</biblScope>
<biblScope unit="issue">6</biblScope>
<biblScope unit="page" from="1318">1318</biblScope>
<biblScope unit="page" to="1320">1320</biblScope>
</imprint>
<idno type="ISSN">0885-3185</idno>
</series>
<idno type="istex">07A65F99973DA9BFA8C22CFE208BE2B92BA3D355</idno>
<idno type="DOI">10.1002/mds.10276</idno>
<idno type="ArticleID">MDS10276</idno>
</biblStruct>
</sourceDesc>
<seriesStmt><idno type="ISSN">0885-3185</idno>
</seriesStmt>
</fileDesc>
<profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Parkinson's disease</term>
<term>atropine</term>
<term>sialorrhea</term>
</keywords>
</textClass>
<langUsage><language ident="en">en</language>
</langUsage>
</profileDesc>
</teiHeader>
<front><div type="abstract" xml:lang="en">Sialorrhea is a relatively common symptom in idiopathic Parkinson's disease and related conditions for which most of the accepted treatments are either highly invasive or may cause substantial systemic side effects. This study describes an open‐label pilot study of sublingual atropine drops for the treatment of sialorrhea in 7 patients (6 with Parkinson's disease, 1 with progressive supranuclear palsy). Participants demonstrated statistically significant declines in saliva production, both objectively and subjectively. Self‐reported drooling severity showed a significant decline between baseline and 180 minutes, t(6) = 3.240 P < 0.025 (η2 = 0.636), and between baseline and 1 week, t(6) = 4.583 P < 0.005 (η2 = 0.778). Objectively measured saliva production decreased significantly between baseline and the 1‐week follow‐up, t(6) = 2.711 P < 0.05 (η2 = 0.551). Delirium occurred in 1 patient (concurrent with a urinary tract infection), and 2 patients experienced worsening of hallucinations (active hallucinosis was concealed by both individuals to allow participation in the trial). The remaining trial participants did not experience any anticholinergic side effects. This trial shows that, in selected patient populations, sublingual atropine is a simple and inexpensive treatment for sialorrhea associated with parkinsonism. © 2002 Movement Disorder Society</div>
</front>
</TEI>
</ISTEX>
<PubMed><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Sublingual atropine for sialorrhea secondary to parkinsonism: a pilot study.</title>
<author><name sortKey="Hyson, H Christopher" sort="Hyson, H Christopher" uniqKey="Hyson H" first="H Christopher" last="Hyson">H Christopher Hyson</name>
<affiliation wicri:level="1"><nlm:affiliation>Movement Disorders Program, London Health Sciences Centre, London, Ontario, Canada.</nlm:affiliation>
<country xml:lang="fr">Canada</country>
<wicri:regionArea>Movement Disorders Program, London Health Sciences Centre, London, Ontario</wicri:regionArea>
<wicri:noRegion>Ontario</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Johnson, Andrew M" sort="Johnson, Andrew M" uniqKey="Johnson A" first="Andrew M" last="Johnson">Andrew M. Johnson</name>
</author>
<author><name sortKey="Jog, Mandar S" sort="Jog, Mandar S" uniqKey="Jog M" first="Mandar S" last="Jog">Mandar S. Jog</name>
</author>
</titleStmt>
<publicationStmt><idno type="wicri:source">PubMed</idno>
<date when="2002">2002</date>
<idno type="RBID">pubmed:12465075</idno>
<idno type="pmid">12465075</idno>
<idno type="doi">10.1002/mds.10276</idno>
<idno type="wicri:Area/PubMed/Corpus">003904</idno>
<idno type="wicri:Area/PubMed/Curation">003904</idno>
<idno type="wicri:Area/PubMed/Checkpoint">003925</idno>
<idno type="wicri:Area/Ncbi/Merge">000947</idno>
<idno type="wicri:Area/Ncbi/Curation">000947</idno>
<idno type="wicri:Area/Ncbi/Checkpoint">000947</idno>
<idno type="wicri:doubleKey">0885-3185:2002:Hyson H:sublingual:atropine:for</idno>
</publicationStmt>
<sourceDesc><biblStruct><analytic><title xml:lang="en">Sublingual atropine for sialorrhea secondary to parkinsonism: a pilot study.</title>
<author><name sortKey="Hyson, H Christopher" sort="Hyson, H Christopher" uniqKey="Hyson H" first="H Christopher" last="Hyson">H Christopher Hyson</name>
<affiliation wicri:level="1"><nlm:affiliation>Movement Disorders Program, London Health Sciences Centre, London, Ontario, Canada.</nlm:affiliation>
<country xml:lang="fr">Canada</country>
<wicri:regionArea>Movement Disorders Program, London Health Sciences Centre, London, Ontario</wicri:regionArea>
<wicri:noRegion>Ontario</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Johnson, Andrew M" sort="Johnson, Andrew M" uniqKey="Johnson A" first="Andrew M" last="Johnson">Andrew M. Johnson</name>
</author>
<author><name sortKey="Jog, Mandar S" sort="Jog, Mandar S" uniqKey="Jog M" first="Mandar S" last="Jog">Mandar S. Jog</name>
</author>
</analytic>
<series><title level="j">Movement disorders : official journal of the Movement Disorder Society</title>
<idno type="ISSN">0885-3185</idno>
<imprint><date when="2002" type="published">2002</date>
</imprint>
</series>
</biblStruct>
</sourceDesc>
</fileDesc>
<profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Administration, Sublingual</term>
<term>Aged</term>
<term>Aged, 80 and over</term>
<term>Atropine (administration & dosage)</term>
<term>Atropine (adverse effects)</term>
<term>Delusions (chemically induced)</term>
<term>Female</term>
<term>Hallucinations (chemically induced)</term>
<term>Humans</term>
<term>Male</term>
<term>Middle Aged</term>
<term>Parkinsonian Disorders (drug therapy)</term>
<term>Pilot Projects</term>
<term>Salivation (drug effects)</term>
<term>Sialorrhea (drug therapy)</term>
<term>Treatment Outcome</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="administration & dosage" xml:lang="en"><term>Atropine</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="adverse effects" xml:lang="en"><term>Atropine</term>
</keywords>
<keywords scheme="MESH" qualifier="chemically induced" xml:lang="en"><term>Delusions</term>
<term>Hallucinations</term>
</keywords>
<keywords scheme="MESH" qualifier="drug effects" xml:lang="en"><term>Salivation</term>
</keywords>
<keywords scheme="MESH" qualifier="drug therapy" xml:lang="en"><term>Parkinsonian Disorders</term>
<term>Sialorrhea</term>
</keywords>
<keywords scheme="MESH" xml:lang="en"><term>Administration, Sublingual</term>
<term>Aged</term>
<term>Aged, 80 and over</term>
<term>Female</term>
<term>Humans</term>
<term>Male</term>
<term>Middle Aged</term>
<term>Pilot Projects</term>
<term>Treatment Outcome</term>
</keywords>
</textClass>
</profileDesc>
</teiHeader>
<front><div type="abstract" xml:lang="en">Sialorrhea is a relatively common symptom in idiopathic Parkinson's disease and related conditions for which most of the accepted treatments are either highly invasive or may cause substantial systemic side effects. This study describes an open-label pilot study of sublingual atropine drops for the treatment of sialorrhea in 7 patients (6 with Parkinson's disease, 1 with progressive supranuclear palsy). Participants demonstrated statistically significant declines in saliva production, both objectively and subjectively. Self-reported drooling severity showed a significant decline between baseline and 180 minutes, t(6) = 3.240 P < 0.025 (eta(2) = 0.636), and between baseline and 1 week, t(6) = 4.583 P < 0.005 (eta(2) = 0.778). Objectively measured saliva production decreased significantly between baseline and the 1-week follow-up, t(6) = 2.711 P < 0.05 (eta(2) = 0.551). Delirium occurred in 1 patient (concurrent with a urinary tract infection), and 2 patients experienced worsening of hallucinations (active hallucinosis was concealed by both individuals to allow participation in the trial). The remaining trial participants did not experience any anticholinergic side effects. This trial shows that, in selected patient populations, sublingual atropine is a simple and inexpensive treatment for sialorrhea associated with parkinsonism.</div>
</front>
</TEI>
</PubMed>
</double>
</record>
Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Santé/explor/MovDisordV3/Data/Main/Merge
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 006284 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Main/Merge/biblio.hfd -nk 006284 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien |wiki= Wicri/Santé |area= MovDisordV3 |flux= Main |étape= Merge |type= RBID |clé= ISTEX:07A65F99973DA9BFA8C22CFE208BE2B92BA3D355 |texte= Sublingual Atropine for sialorrhea secondary to parkinsonism: A pilot study }}
![]() | This area was generated with Dilib version V0.6.23. | ![]() |